Nuzenio

Phase Iii Visionary

Phase Iii Visionary news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study - Slideshow (OTCMKTS:OTSKY) 2026-08-06 - Seeking AlphaSeeking Alpha · Thu, 06 Aug 2026 12:44:51 GMTOtsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy - DealroomDealroom · Wed, 05 Aug 2026 04:43:21 GMTOtsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business TimesInternational Business Times · Tue, 04 Aug 2026 14:43:23 GMTOtsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 14:31:49 GMTOtsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Show - The National Law ReviewThe National Law Review · Tue, 04 Aug 2026 07:06:40 GMTOtsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business OutlookWorld Business Outlook · Tue, 04 Aug 2026 05:40:13 GMTOtsuka's Voyxact Halts Kidney Function Decline In Phase 3 IgAN Trial, Strengthening FDA Approval Bid - londoninsider.co.uklondoninsider.co.uk · Mon, 03 Aug 2026 23:18:29 GMTIn a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 21:00:00 GMT

Timeline

Thu, 06 Aug 2026 12:44:51 GMTOtsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study - Slideshow (OTCMKTS:OTSKY) 2026-08-06 - Seeking Alpha
Wed, 05 Aug 2026 04:43:21 GMTOtsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy - Dealroom
Tue, 04 Aug 2026 14:43:23 GMTOtsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business Times
Tue, 04 Aug 2026 14:31:49 GMTOtsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - Clinical Trials Arena
Tue, 04 Aug 2026 07:06:40 GMTOtsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Show - The National Law Review
Tue, 04 Aug 2026 05:40:13 GMTOtsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business Outlook

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Phase Iii Visionary.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.